CN101128418A - 4-羟基异亮氨酸的非对映异构体及其用途 - Google Patents

4-羟基异亮氨酸的非对映异构体及其用途 Download PDF

Info

Publication number
CN101128418A
CN101128418A CNA2006800050682A CN200680005068A CN101128418A CN 101128418 A CN101128418 A CN 101128418A CN A2006800050682 A CNA2006800050682 A CN A2006800050682A CN 200680005068 A CN200680005068 A CN 200680005068A CN 101128418 A CN101128418 A CN 101128418A
Authority
CN
China
Prior art keywords
compound
lactone
diabetes
prodrug
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800050682A
Other languages
English (en)
Chinese (zh)
Inventor
克劳德·哥古尔立特
查尔斯·密欧斯科维他斯基
艾伦·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innodia Inc
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Original Assignee
Innodia Inc
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innodia Inc, Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I filed Critical Innodia Inc
Publication of CN101128418A publication Critical patent/CN101128418A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
CNA2006800050682A 2005-02-18 2006-02-17 4-羟基异亮氨酸的非对映异构体及其用途 Pending CN101128418A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65441305P 2005-02-18 2005-02-18
US60/654,413 2005-02-18

Publications (1)

Publication Number Publication Date
CN101128418A true CN101128418A (zh) 2008-02-20

Family

ID=37086084

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800050682A Pending CN101128418A (zh) 2005-02-18 2006-02-17 4-羟基异亮氨酸的非对映异构体及其用途

Country Status (8)

Country Link
EP (1) EP1853552A2 (ja)
JP (1) JP2008530198A (ja)
CN (1) CN101128418A (ja)
AU (1) AU2006242851A1 (ja)
BR (1) BRPI0607140A2 (ja)
CA (1) CA2598491A1 (ja)
MX (1) MX2007009985A (ja)
WO (1) WO2006117696A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112089710A (zh) * 2020-08-07 2020-12-18 郑州大学 4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2008154743A1 (en) * 2007-06-19 2008-12-24 Innodia Inc. Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof
US20110136911A1 (en) * 2007-12-20 2011-06-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
JP6800968B2 (ja) 2015-10-23 2020-12-16 ナビター ファーマシューティカルズ， インコーポレイテッド セストリン−ｇａｔｏｒ２相互作用のモジュレーターおよびその使用
JP7179015B2 (ja) 2017-04-26 2022-11-28 ナビター ファーマシューティカルズ， インコーポレイテッド Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
EP3870158A4 (en) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
AU2020376950A1 (en) 2019-11-01 2022-06-09 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
BRPI0415781A (pt) * 2003-10-27 2006-12-26 Innodia Inc método para o tratamento de diabetes em um paciente e kit farmacêutico
EP1657236A1 (en) * 2004-11-10 2006-05-17 Centre National De La Recherche Scientifique (Cnrs) Method for preparing diastereoisomers of 4-hydroxy isoleucine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112089710A (zh) * 2020-08-07 2020-12-18 郑州大学 4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
BRPI0607140A2 (pt) 2009-08-11
JP2008530198A (ja) 2008-08-07
WO2006117696A2 (en) 2006-11-09
CA2598491A1 (en) 2006-11-09
EP1853552A2 (en) 2007-11-14
AU2006242851A1 (en) 2006-11-09
WO2006117696A3 (en) 2007-01-25
MX2007009985A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
CN101128418A (zh) 4-羟基异亮氨酸的非对映异构体及其用途
CA2622472C (en) Dipeptidyl peptidase inhibitors for treating diabetes
JP5837657B2 (ja) 糖尿病の処置方法
US20190381045A1 (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
CN101193852A (zh) 4-羟基异亮氨酸类似物及其用途
EP2134348B1 (en) Weekly administration of dipeptidyl peptidase inhibitors
CN102295606A (zh) 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
CN103906748A (zh) 2-氨基-4-(吡啶-2-基)-5,6-二氢-4h-1,3-*嗪衍生物及其作为bace-1和/或bace-2抑制剂的用途
CA2663279A1 (en) Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
CN102918027A (zh) Gpr119受体调节剂和对与所述受体有关的障碍的治疗
CN101252926A (zh) 用于预防和治疗肥胖症及相关综合征的化合物与组合物
TW200918049A (en) Compounds useful as medicaments
CN103189359A (zh) 5-ht2c激动剂的光学活性酸盐
EA024207B1 (ru) Пиразольные соединения
CA3075705A1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US20220152004A1 (en) Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
JP2008500955A (ja) 糖尿病の治療に使用するための方法及び組成物
WO2009128360A1 (ja) 糖尿病治療剤
DE60102812T2 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
CN114929218A (zh) 使用整联蛋白抑制剂组合治疗肝脏疾病
US20190231787A1 (en) Methods and compounds for treating alcohol use disorders and associated diseases
WO2010050422A1 (ja) 糖尿病治療剤
CN101638395A (zh) 二苯基乙烯化合物的杂环类似物及其应用
RU2648467C2 (ru) Профилактическое или терапевтическое лекарственное средство для лечения запора
US11813274B2 (en) Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120255

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080220

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120255

Country of ref document: HK